To investigate the response of patients with MED12 mutations to RTK inhibitors, we utilized the GENIE BPC NSCLC v2.0 public database from the AACR Project GENIE, accessed through cBioPortal, to select an appropriate patient cohort [40, 41]. Here, MED12 is linked to non-small cell lung carcinoma.